Human Insulin Mix 50:50 — Competitive Intelligence Brief

Human Insulin Mix 50:50 (Human Insulin Mix 50:50) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin preparation. Area: Diabetes.

phase 3 Insulin preparation Insulin receptor Diabetes Small molecule

Target snapshot

Human Insulin Mix 50:50 (Human Insulin Mix 50:50) — Eli Lilly and Company. Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human Insulin Mix 50:50 TARGET	Human Insulin Mix 50:50	Eli Lilly and Company	phase 3	Insulin preparation	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin preparation class)

1. Eli Lilly and Company · 1 drug in this class
2. University Health Network, Toronto · 1 drug in this class